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Background: Diagnosis of mesothelioma based on death certificate is subject to misclassification, which may bias the results
of epidemiology studies. A high proportion of mesothelioma harbor mutations in the BRCA1-associated protein 1 (BAP1) gene.
Methods: We searched medical and pathology records and specimens for 127 workers from a textile-asbestos factory in Italy
who died during 1963–2013 with a diagnosis of pleural or peritoneal neoplasm or mesothelioma on death certificate, to
confirm the diagnosis with immunohistochemistry markers. We calculated the odds ratio of confirmation by selected
characteristics and asbestos exposure variables. When sufficient pathology material was available, we analyzed BAP1 protein
expression.
Results: The diagnosis of mesothelioma was histologically confirmed for 35 cases (27.6%); 5 cases were classified as non-
mesothelioma (3.9%), for 33 cases a mention of mesothelioma was found on record but no sufficient material was available for
revision (26.0%); no records were available for 54 cases (death-certificate-only 42.5%). Diagnostic confirmation was not
associated with sex, location of the neoplasm, age, or duration of employment; however, there was a significant association
with time since first employment (P for linear trend 0.04). An association between duration of employment and time since first
employment was observed for confirmed cases but not for death-certificate-only cases. BAP1 protein was lost in 18/35 cases
(51.4%), without an association with sex, location, age, indices of asbestos exposure, or survival.
Conclusions: We were able to confirm by immunohistochemistry a small proportion of mesothelioma diagnoses on
certificates of deceased asbestos workers, and confirmation correlated with latency of asbestos exposure but not other
characteristics. BAP1 protein loss is a frequent event in mesothelioma of asbestos-exposed workers, but does not correlate with
exposure.
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Introduction
We recently reported the results of the mortality analysis of a
cohort of former workers of an asbestos textile factory in
Northern Italy [1]. These workers experienced very high exposure
to asbestos, including crocidolite, which resulted in a high num-
ber of deaths from pleural and peritoneal mesothelioma.
Death certificates have been traditionally used to identify cases
of malignant neoplasms in occupational studied, but it is know
that this approach entails some degree of misclassification [2].
This issue is particular relevant for malignant mesothelioma. On
the one hand, mesothelioma can be misdiagnosed as primary or
secondary lung cancer, or be ignored all together (false negatives).
On the other hand, other primary or secondary thoracic neo-
plasms, mainly peripheral lung cancer, can be wrongly diagnosed
as mesothelioma (false positives): this problem may be exacer-
bated if the person in charge of compiling the cause of death on
the certificate has knowledge of previous asbestos exposure of the
decedent [3].
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Several authors have compared the diagnosis of mesothelioma
(or pleural/peritoneal tumor) on death certificates with medical
records or pathology reports, including autopsy [4–12]. These
studies reported specificity and sensitivity of death certificate-
based diagnoses in the range 40%–85%, and, in studies consider-
ing multiple types of cancer, both specificity and sensitivity were
lower for mesothelioma than for other cancers, in particular lung
cancer. In general, older studies reported lower sensitivity, perito-
neal mesothelioma was more frequently misclassified than pleu-
ral, and there was a tendency toward lower reliability of such
certificates with increasing age at death. With a few exceptions
(see Ref. [9]), these studies were based on a relatively small num-
ber of deaths, and the validity of death certificates was not associ-
ated with indicators of asbestos exposure.
BRCA1-associated protein 1 (BAP1) is a nuclear deubiquiti-
nating enzyme that acts as a tumor suppressor gene and plays a
role in various cellular processes [13–16]. BAP1 gene is located
on chromosome 3p21, a region that harbors both germline
and somatic gene alterations identified in both hereditary and
sporadic mesothelioma [14, 17–20]. Alteration of BAP1 at genetic
level, independently of the underlying mechanism (e.g. gene dele-
tion or insertion, point mutation, gain, or loss), translates into
nuclear loss of BAP1 expression at protein level, identifiable by
immunohistochemistry (IHC) with high specificity [18, 20, 21].
Furthermore, emerging evidence supports a role of BAP1 gene
alteration to enhanced cancer susceptibility. Kadariya et al. [16]
have recently shown in mouse models that there is a possible
gene–environment interaction between BAP1 mutations and
asbestos exposure in the development of this disease. In this con-
text, Napolitano et al. [22] found that in mice carrying heterozy-
gous germline BAP1 mutations mesothelioma develops upon
exposure to asbestos levels that rarely cause the disease in wild-
type mice.
In this analysis based on the cohort of Italian asbestos cohort
[1], we aimed at (i) evaluating the odds ratio (OR) of diagnostic
confirmation according to selected variables; (ii) evaluating the
mortality rate ratio (MRR) for confirmed cases versus non-con-
firmed cases, according to several indices of asbestos exposure;
and (iii) in the subset of confirmed cases, evaluating the associa-
tion between selected variables and the expression of BAP1 pro-
tein, whose gene mutation in mice is associated with higher
susceptibility to mesothelioma upon low levels of exposure to
asbestos.
Methods
The study population has been described in previous reports [1, 23, 24]
and includes 1083 women and 894 men who had worked in an asbestos
textile factory sited in the metropolitan area of Turin in Piedmont,
Northern Italy, between 1946 and 1984. The main type of asbestos used
in the plant was chrysotile, but crocidolite was also present; the cohort
was defined based on employment records obtained from personnel
records at the factory. Several time-related exposure variables were calcu-
lated, including time since first employment, duration of employment,
and time since last employment. Vital status and causes of death were
ascertained up to 2013 through population registers and death certifi-
cates from local authorities. A total of 127 cohort members were reported
dead between 1963 and 2013 with a diagnosis of pleural or peritoneal
cancer (or mesothelioma) on death certificate, 108 of themwere included
in the most recent mortality analysis, which was restricted to 1977
workers who were employed after 1946 [1], while for 11 decedents the
diagnosis of pleural or peritoneal cancer or mesothelioma was reported
among the contributory causes of death, and 8 did not satisfy the inclu-
sion criteria of the mortality, as they had not worked in the asbestos tex-
tile factory after 1946.
As first step of the validation study, we sought medical or pathology
records of all 127 cohort members with a diagnosis of pleural or perito-
neal cancer or mesothelioma on the death certificate. We checked the
archives of the pathology laboratories in the main hospitals of the metro-
politan area of Turin. For subjects who died in different areas, we sought
information from the main hospitals of the respective areas, as reported
on the death certificates. Finally we contacted the regional mesothelioma
registries [25], and obtained information on the cases registered in the
registry of the Piedmont region.
We abstracted the pathology and clinical information according to a
standard form, including date of diagnosis, histologic type, and results of
IHC tests, if available. Abstraction was made blind of indicators of asbes-
tos exposure. For decedents with a mention of mesothelioma on the
pathology or medical records, we sought to obtain a pathology specimen
(typically a formalin-fixed, paraffin-embedded sample from effusion or
biopsy or surgery, or slides) for pathology review and BAP1 protein
expression analysis.
Morphological and IHC revision of the specimens was made by two
pathologists (LR, MP) according to established guidelines [26]. Further
IHC stains were carried out in those cases that did not meet the guidelines
(at least two positive and two negative mesothelioma markers, [26]).
Briefly, 5-lm-thick sections from paraffin blocks were processed using
an automated immunostainer (Ventana BenchMark AutoStainer,
Ventana Medical Systems, Tucson, AZ, USA or Omnis Immunostainer,
Dako, Glostrup, Denmark) with the following primary antibody, when
applicable: Calretinin (1 : 100, rabbit polyclonal #RB-9002-R7, Thermo
Fisher Scientific, Waltham, MA), Wilms tumor-1 antigen (WT1, 1 : 10,
mouse clone 6FH2, Thermo Fisher Scientific), Cytokeratin 5 (1 : 100,
mouse clone D5, ImPath, Menarini Diagnostics, Bagno a Ripoli, Italy),
Podoplanin (1 : 150; mouse clone D2-40, Dako/Agilent, Glostrup,
Denmark), Pancytokeratin (1 : 500, mouse clone AE1/AE3, Dako), epi-
thelial membrane antigen (1 : 6000, mouse clone E29, Dako), Carcino-
embrionic antigen (CEA, 1 : 15 000, rabbit polyclonal IR52661-2, Dako),
TTF1 (8G7G3/1, Dako) and BAP1 (1 : 100, rabbit clone-C4, Santa-Cruz
Biotechnology, Santa Cruz, CA). IHC reactions were considered positive
when a weak-to-strong nuclear, cytoplasmic or membrane staining was
shown. All reactions where validated by internal or external control, in
particular, for BAP1 IHC a complete absence of nuclear staining was con-
sidered true negative in the presence of nuclear-positive non-neoplastic
cells, such as vascular endothelium or inflammatory cells, that acted as
internal positive controls.
At the end of the pathology revision, study subjects were divided into
four groups: (i) IHC-confirmed mesothelioma (positive after histologic
review and IHC staining; these cases were analyzed for BAP1 protein
expression); (ii) non-mesothelioma (either diagnosis other than mesothe-
lioma on pathology or medical records, or lack of confirmation after
histology review and/or IHC staining); (iii) record-based mesothelioma
(diagnosis of mesothelioma from pathology or medical records, without
sufficient material for histologic review and IHC staining); (iv) death-cer-
tificate-only mesothelioma (no medical or pathology records; diagnosis
rests on death certificate).
We conducted several statistical analyses. First, we estimated the ORs
of diagnostic confirmation after review [i.e. group (i) above versus all
other groups] according to demographic and clinical characteristics (sex,
age at death, calendar period of death, pleural versus peritoneal location),
as well as selected indices of asbestos exposure (time since first exposure,
time since cessation of exposure, duration of exposure). We used the
same cut points for the categories of the indices of exposure as in our
original publication onmortality [1]. Sensitivity analyses were conducted
with different group comparisons, e.g. group (i) versus groups (iii) and
(iv), excluding group (ii).
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Second, we repeated the recently published mortality analysis [1] by
calculating MRRs for each of the four groups of decedents described
above (decedents from pleural or peritoneal cancer belonging to the
other groups were excluded from this analysis). This analysis was
restricted to the 108 decedents included in the original mortality analysis;
in particular, it excluded deaths and person-years above 85 years of age.
Third, in an analysis restricted to confirmed cases with BAP1 protein
loss of expression, we estimated the OR of carrying a BAP1 protein loss
according to demographic, clinical and exposure variables. Finally, we
conducted an analysis of survival of confirmed cases of mesothelioma
according to BAP1 protein status.
Multivariable logistic regression models were fit to estimate ORs after
adjustment for sex, age at death, pleural/peritoneal location, duration of
employment, and time since first employment. MRRs were calculated by
fitting Poisson regression models [27], adjusted for sex and age. Age and
the exposure variables were introduced in the Poisson regression models
as time-varying covariates; age was parameterized in the models as
ageþ age2. To assess the presence of linear trends across levels of ordinal
variables, we evaluated the Wald v2 statistic after fitting regression mod-
els including a linear term for the covariate of interest. Survival analyses
were conducted by calculating Kaplan–Meier estimators and by fitting
Cox regression models including the same factors as the logistic models.
The STATA and SAS statistical packages were used [28, 29].
Results
Supplementary Figure S1, available at Annals of Oncology online,
illustrates the process to validate the causes of death and to obtain
and review pathology specimens. Out of the 127 decedents, no
sufficient information was obtained for 54 (death-certificate-
only mesothelioma, 42.5%); among the other cases, pathology
samples adequate for review were obtained from 35 of them, and
the diagnosis of mesothelioma was confirmed in all (IHC-con-
firmed mesothelioma, 27.6%); a total of 5 cases were classified as
non-mesothelioma (3.9%) due to a diagnosis other than meso-
thelioma on medical or pathology report for four cases (i.e. 1
adenocarcinoma, 1 ovarian carcinoma, 1 peritoneal carcinoma; 1
pleurisy), and to the information received from the regional mes-
othelioma registry for 1 case; for the remaining 33 cases a men-
tion of mesothelioma was found on a medical or pathology
report but sufficient material for the revision was not available:
these cases were classified as record-based mesothelioma
(26.0%).
In particular, out of the 35 samples which were reviewed 30
were histological samples (16 from the pleura and 14 from the
peritoneum) and 5 were cytological samples (2 pleural and 3
peritoneal).
Regarding histotype of the cases with histological sample, 22
were epithelioid (12 peritoneal and 10 pleural), 7 biphasic (2 peri-
toneal and 5 pleural) and 1 sarcomatous pleural mesothelioma.
The dates of death of IHC-confirmed mesothelioma cases were
more recent than those of other groups of cases; in particular,
there were no IHC-confirmed cases among the 31 cases who died
before 1993, and only 6 cases among the 30 who died between
1993 and 1999.
A total of 76 of the 127 cases were also listed in the Regional
Mesothelioma Registry of Piedmont: among them 56 were classi-
fied by the Registry as certain mesothelioma, 19 as probable or
possible mesothelioma, and 1 as non-mesothelioma. If we con-
sider our diagnostic validation as gold standard, the sensitivity of
the classification of the Registry (certain confirmed
mesothelioma versus other) was 83% and the specificity 34%
(results not shown in detail).
In the univariate analysis, there was no difference in the pro-
portion of IHC-confirmed cases between pleural and peritoneal
cases, or according to age at death, while the proportion of IHC-
confirmed cases was higher among women (30.9%) compared
with men (17.7%, P-value of difference¼ 0.002; results not
shown in detail).
The results of the multivariate logistic regression analysis are
reported in Table 1. There was no association between IHC-based
diagnostic confirmation and sex, site of the neoplasm, age, or
duration of employment; however, there was a significant associ-
ation with time since first employment. The exclusion of cases
whose confirmation was based on cytologic samples has very lim-
ited impact on the results (not shown in detail). Additional analy-
ses based on different strategies (e.g. excluding the five cases
confirmed as non-mesothelioma) provided similar results (not
shown in detail).
The results of the internal analysis of indicators of asbestos
exposure are reported in Table 2. The number of confirmed non-
mesothelioma cases was too small to be analyzed separately.
There was an association between duration of employment and
time since first employment and IHC-confirmed mesothelioma,
while this association was not present for death-certificate-only
mesothelioma.
Table 1. Odds ratios of diagnostic confirmation
Variable Na OR 95% CI P trend
Sex
Male 9/32 1.00 Ref.
Female 26/60 0.95 0.35–2.60
Site
Pleura 17/50 1.00 Ref.
Peritoneum 18/42 0.69 0.27–1.78
Age at death (years) 0.28
<60 15/35 1.00 Ref.
60–69 9/30 0.69 0.22–2.18
70þ 11/27 0.77 0.23–2.62
Duration of asbestos
exposure (years)
0.45
<1.0 6/27 1.00 Ref.
1.0–2.9 7/19 1.86 0.50–6.91
3.0–9.9 14/17 5.98 1.55–23.0
10.0þ 8/29 1.42 0.40–4.98
Time since first asbestos
exposure (years)
0.04
<25.0 1/17 1.00 Ref.
25.0–34.9 11/31 7.69 0.81–72.9
35.0–44.9 16/27 18.0 1.80–179
45.0þ 7/17 14.3 1.20–170
aNumber of IHC-confirmed/other cases.
OR, odds ratio of IHC-based confirmation, adjusted for the variables in
the table; CI, confidence interval; P trend, P-value of test for linear trend;
Ref., reference category.
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BAP1 IHC protein expression was investigated in the 35 IHC-
confirmed cases; 18/35 (51.4%) were negative for nuclear BAP1
expression (loss of expression), thus predicting a gene alteration.
These cases were distributed as follows: 5/5 cytological samples,
10/22 epithelioid mesothelioma (4/12 peritoneal and 6/10 pleu-
ral), 3/7 biphasic mesothelioma (1/2 peritoneal and 2/5 pleural),
and 0/1 sarcomatous mesothelioma. The results of the multivari-
ate logistic regression are shown in supplementary Table S1,
available at Annals of Oncology online: for none of the factors
included in the analysis (sex, age at diagnosis, tumor site, dura-
tion of employment, and time since first employment) there was
an association with BAP1 protein expression loss.
No difference in survival was detected according to BAP1 pro-
tein expression (Figure 1); the P-value of the Kaplan–Meier test
was 0.30. This result was confirmed in a multivariate Cox regres-
sion analysis (hazard ratio for negative BAP1 expression, after
adjustment for sex, site of neoplasm, age at death, duration of
employment and time since first employment 1.76; 95% confi-
dence interval 0.72–4.32).
Discussion
Our study showed that for only a relatively small proportion of
deaths from mesothelioma occurring among members of a his-
torical cohort of asbestos workers (28% in our study) is possible
to confirm the diagnosis on the basis of samples retrieved from
the archives of pathology laboratories. It is notable in particular
that despite our search efforts, no additional information was
obtained for 43% of cases in our series. These results are similar
to those obtained in similar validation studies of death certificates
in historical cohorts [5, 7, 9], and in part reflect the difficulty in
obtaining data or pathology samples of cases who died 15 or
more years ago: after excluding cohort members who died
before 2000, the proportion of confirmed cases increased to
44% (29/66). In addition, our study suggests that low sensitivity
in the classification of ‘certain’ confirmed mesothelioma cases
may affect population-based registries of mesothelioma which do
not actively seek pathologic evidence.
Table 2. Mortality rate ratios for IHC-confirmed, record-based and death-certificate-only mesothelioma, according to selected indices of asbestos exposure
IHC-confirmed
mesothelioma (N5 31)
Record-based
mesothelioma (N5 30)
Death-certificate-only
mesothelioma (N5 44)
n MRR (95% CI) n MRR (95% CI) n MRR (95% CI)
Age at first employment
<30 22 1 (Ref.) 19 1 (Ref.) 27 1 (Ref.)
30 9 0.43 (0.19–0.99) 11 0.88 (0.40–1.94) 17 0.55 (0.28–1.05)
Duration of employment
<1 5 1 (Ref.) 7 1 (Ref.) 15 1 (Ref.)
1–4 11 2.59 (0.90–7.48) 6 0.98 (0.33–2.91) 17 1.44 (0.72–2.90)
5–9 8 2.94 (0.96–9.03) 3 0.75 (0.19–2.92) 5 0.69 (0.25–1.90)
10 7 2.44 (0.77–7.73) 14 3.39 (1.36–8.45) 7 0.87 (0.35–2.15)
P trend 0.12 0.008 0.53
Time since first employment
<30 6 1 (Ref.) 10 1 (Ref.) 18 1 (Ref.)
30–44 19 4.24 (1.45–12.39) 15 1.52 (0.61–3.77) 21 1.27 (0.63–2.55)
45 6 4.16 (1.02–17.00) 5 1.57 (0.43–5.74) 5 0.89 (0.29–2.77)
P trend 0.03 0.42 0.93
Time since last employment
<30 15 1 (Ref.) 20 1 (Ref.) 26 1 (Ref.)
30 16 1.47 (0.67–3.21) 10 0.61 (0.27–1.37) 18 1.02 (0.53–1.97)
Non-mesothelioma cases (n¼ 3) were not analyzed because of small numbers. In each analysis mesothelioma cases belonging to other categories were
excluded. Deaths and person-years occurring at age85 years were excluded.
MRR, Mortality rate ratios adjusted for age and sex; CI, confidence interval; N, number of deaths; Ref., reference category; P trend, P-value of test for linear trend.
Continuous line: Expression positive; Dotted line: Expression negative
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Figure 1. Survival by BAP1 protein expression.
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Our study is among the first to correlate the probability of
diagnostic confirmation with clinical and environmental charac-
teristics of the cases. No differences were found according to sex,
age, and site of the mesothelioma, while time since first employ-
ment (a proxy for time since first asbestos exposure) was signifi-
cantly associated a higher probability of confirmation, and
duration of employment (a proxy for duration of asbestos
exposure) was not. These results are consistent with the notion,
supported by consistent findings from occupational epidemiol-
ogy studies, that time since first exposure (i.e. latency) is the key
risk factor of mesothelioma [30]. The results of the prospective
mortality analysis provide support to the diagnostic validation,
since the association with time since first employment is
strongest among confirmed cases and absent among undeter-
mined cases.
The analysis of BAP1 protein expression was hampered by the
small number of cases with available archival material, and cau-
tion should be used in the interpretation of these results.
Nonetheless, it provided some evidence of lack of association
with exposure to asbestos, keeping in mind that all cases in this
study were exposed to this carcinogen, and we could only differ-
entiate them according to duration of employment or time since
first employment. Other studies also failed to detect and associa-
tion between asbestos exposure and either BAP1 protein expres-
sion or gene mutation [31, 32]: given the very heavy exposure
experienced by workers in this cohort, our results provide novel
evidence of a lack of association between asbestos exposure and
BAP1 protein loss only, also in these extreme exposure circum-
stances. Our findings are in line with literature data that reported
a higher BAP1 protein loss in epithelioid than other histotypes
[21, 33] and primarily in pleural rather than peritoneal mesothe-
lioma (55% versus 47%).
Our results of lack of difference in survival according to BAP1
protein expression are at odds with those of previous studies and
meta-analyses [33–36], which suggest a survival benefit for cases
harboring a genetic alteration in this gene. This may be due to the
small number of cases included in our analysis.
Strengths of our study include the uniqueness of the cohort,
characterized by high asbestos exposure and high risk of meso-
thelioma, and the extensive effort to retrieve medical records
and pathology samples for the validation of diagnosis and the
analysis of BAP1 protein expression. The small number of cases
with sufficient material to confirm or disprove the diagnosis
and to conduct the BAP1 protein analysis represents the main
limitation of the study. The lack of individual data on level of
exposure to asbestos is an additional limitation, which was
addressed by analyzing proxy indicators such as duration of
exposure.
In conclusion, our study shows that for a relatively large pro-
portion of members of historical cohorts of asbestos workers, the
information on pleural or peritoneal cancer/mesothelioma
reported on death certificates cannot be validated through medi-
cal or pathology records, and even less so with review of pathol-
ogy material. While the temporal and geographic features of our
cohort make difficult to generalize the results to other popula-
tions, it is plausible that the general patterns we identified are
applicable outside our study population.
Funding
None declared.
Disclosure
The authors have declared no conflicts of interest.
References
1. Pira E, Romano C, Violante FS et al. Updated mortality study of a cohort
of asbestos textile workers. Cancer Med 2016; 5(9): 2623–2628.
2. Flanders WD. Inaccuracies of death certificate information. Epidemiology
1992; 3(1): 3–5.
3. Siemiatycki J, Boffetta P. Invited commentary: is it possible to investigate
the quantitative relation between asbestos and mesothelioma in a
community-based study? Am J Epidemiol 1998; 148(2): 143–147.
4. Newhouse ML, Wagner JC. Validation of death certificates in asbestos
workers. Br J Ind Med 1969; 26(4): 302–307.
5. Newhouse ML. Mesothelioma and the death certificate. Lancet 1982;
2(8305): 991.
6. Lilienfeld DE, Gunderson PD. The “missing cases” of pleural malignant
mesothelioma in Minnesota, 1979–81: preliminary report. Public Health
Rep 1986; 101: 395–399.
7. Connelly RR, Spirtas R, Myers MH et al. Demographic patterns for
mesothelioma in the United States. J Natl Cancer Inst 1987; 78(6):
1053–1060.
8. Ribak J, Lilis R, Suzuki Y et al. Death certificate categorization of malig-
nant pleural and peritoneal mesothelioma in a cohort of asbestos insula-
tion workers. J Soc OccupMed 1991; 41(3): 137–139.
9. Selikoff IJ. Death certificates in epidemiological studies, including occu-
pational hazards: inaccuracies in occupational categories. Am J Ind Med
1992; 22(4): 493–504.
10. Bruno C, Comba P, Maiozzi P, Vetrugno T. Accuracy of death certifica-
tion of pleural mesothelioma in Italy. Eur J Epidemiol 1996; 12(4):
421–423.
11. Okello C, Treasure T, Nicholson AG et al. Certified causes of death in
patients with mesothelioma in South East England. BMC Cancer 2009;
9(1): 28.
12. Wojcik NC, Schnatter AR, Huebner WW. Mesothelioma in occupational
cohort studies: methodological considerations. J Occup Environ Med
2014; 56(1): 47–51.
13. Ventii KH, Devi NS, Friedrich KL et al. BRCA1- associated protein-1 is a
tumor suppressor that requires deubiquitinating activity and nuclear
localization. Cancer Res 2008; 68(17): 6953–6962.
14. Testa JR, Cheung M, Pei J et al. Germline BAP1 mutations predispose to
malignant mesothelioma. Nat Genet 2011; 43(10): 1022–1025.
15. Yu H, Pak H, Hammond-Martel I et al. Tumor suppressor and deubiqui-
tinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad
Sci USA 2014; 111(1): 285–290.
16. Kadariya Y, Menges CW, Talarchek J et al. Inflammation-related
IL1beta/IL1R signaling promotes the development of asbestos-induced
malignant mesothelioma. Cancer Prev Res 2016; 9(5): 406–414.
17. Betti M, Casalone E, Ferrante D et al. Inference on germline BAP1muta-
tions and asbestos exposure from the analysis of familial and sporadic
mesothelioma in a high-risk area. Genes Chromosomes Cancer 2015;
54(1): 51–62.
18. Bott M, Brevet M, Taylor BS et al. The nuclear deubiquitinase BAP1 is
commonly inactivated by somatic mutations and 3p21.1 losses in malig-
nant pleural mesothelioma. Nat Genet 2011; 43(7): 668–672.
19. Yoshikawa Y, Sato A, Tsujimura T et al. Frequent inactivation of the
BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 2012;
103(5): 868–874.
20. Nasu M, Emi M, Pastorino S et al. High Incidence of somatic BAP1 alter-
ations in sporadic malignant mesothelioma. J Thorac Oncol 2015; 10(4):
565–576.
Original article Annals of Oncology
488 | Boffetta et al. Volume 29 | Issue 2 | 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/annonc/article-abstract/29/2/484/4676036 by U
niversity of Torino user on 30 O
ctober 2018
21. Righi L, Duregon E, Vatrano S et al. BRCA1-Associated Protein 1
(BAP1) immunohistochemical expression as a diagnostic tool in malig-
nant pleural mesothelioma classification: a large retrospective study. J
Thorac Oncol 2016; 11(11): 2006–2017.
22. Napolitano A, Pellegrini L, Dey A et al. Minimal asbestos exposure in
germline BAP1 heterozygous mice is associated with deregulated inflam-
matory response and increased risk of mesothelioma. Oncogene 2016;
35(15): 1996–2002.
23. Pira E, Pelucchi C, Piolatto PG et al. First and subsequent asbestos expo-
sures in relation to mesothelioma and lung cancer mortality. Br J Cancer
2007; 97(9): 1300–1304.
24. Pira E, Pelucchi C, Buffoni L et al. Cancer mortality in a cohort of asbes-
tos textile workers. Br J Cancer 2005; 92(3): 580–586.
25. Nesti M, Marinaccio A, Gennaro V et al. Epidemiologic surveillance for
primary prevention of malignant mesothelioma: the Italian experience.
Med Lav 2005; 96(4): 338–346.
26. Husain AN, Colby T, Ordonez N et al. Guidelines for pathologic diagno-
sis of malignant mesothelioma: 2012 update of the consensus statement
from the International Mesothelioma Interest Group. Arch Pathol Lab
Med 2013; 137(5): 647–667.
27. Breslow N, Day N. Statistical Methods in Cancer Research. Vol II. The
Design and Analysis of Cohort Studies. IARC Sci Publ No. 82. Lyon:
International Agency for Research on Cancer, 1987.
28. StataCorp. STATA Version 14.0. College Station, TX: StataCorp, 2015.
29. SAS Institute Inc. SAS Version 9.4. Cary, NC: SAS Institute, 2013.
30. Peto J, Seidman H, Selikoff IJ. Mesothelioma mortality in asbestos work-
ers: implications for models of carcinogenesis and risk assessment. Br J
Cancer 1982; 45(1): 124–135.
31. Arzt L, Quehenberger F, Halbwedl I et al. BAP1 protein is a progression
factor in malignant pleural mesothelioma. Pathol Oncol Res 2014; 20(1):
145–151.
32. Shinozaki-Ushiku A, Ushiku T, Morita S et al. Diagnostic utility of BAP1
and EZH2 expression in malignant mesothelioma. Histopathology 2017;
70(5): 722–733.
33. Leblay N, Lepretre F, Le Stang N et al. BAP1 is altered by copy number
loss, mutation, and/or loss of protein expression in more than 70% of
malignant peritoneal mesotheliomas. J Thorac Oncol 2017; 12(4):
724–733.
34. Baumann F, Flores E, Napolitano A et al. Mesothelioma patients with
germline BAP1 mutations have 7-fold improved long-term survival.
Carcinogenesis 2015; 36(1): 76–81.
35. Farzin M, Toon CW, Clarkson A et al. Loss of expression of BAP1 pre-
dicts longer survival in mesothelioma. Pathology 2015; 47(4): 302–307.
36. Luchini C, Veronese N, Yachida S et al. Different prognostic roles of
tumor suppressor gene BAP1 in cancer: a systematic review with meta-
analysis. Genes Chromosomes Cancer 2016; 55(10): 7419.
Annals of Oncology Original article
Volume 29 | Issue 2 | 2018 doi:10.1093/annonc/mdx762 | 489
D
ow
nloaded from
 https://academ
ic.oup.com
/annonc/article-abstract/29/2/484/4676036 by U
niversity of Torino user on 30 O
ctober 2018
